Featured Article

Lindus Health, a UK clinical trials startup backed by Peter Thiel, raises $18M

London startup has the antiquated clinical trials sector in its crosshairs

Comment

Lindus Health founders
Image Credits: Lindus Health // cofounders Meri Beckwith, Nik Haldimann and Michael Young

Clinical trials are the cornerstone of modern medical research, serving the evidence required to prove (or disprove) the safety and efficacy of a new treatment. However, clinical trials are also costly, resource-intensive endeavors that can take many years to reach a stage where a drug or device is deemed ready for a wide-scale rollout.

This is something that Lindus Health is setting out to address, touting itself as a “next-gen contract research organization” (CRO) that makes it faster and easier to run clinical trials. The U.K. startup today announced it has raised $18 million in a Series A round of funding from big-name backers including Spotify investor Creandum, and billionaire entrepreneur Peter Thiel.

Founded out of London in 2021, Lindus was born from observations and frustrations encountered directly by two of the company’s founders. A former venture capitalist at Omers Ventures, Meri Beckwith had direct knowledge of clinical trials through his work with healthtech startups.

“I worked for a bit in venture capital, and I came across companies running their own clinical trials,” Beckwith explained to TechCrunch. “Everyone was universally frustrated with the outcomes. Everyone just constantly complained about how long clinical trials took, how the outcomes were always bad, and there were always mistakes. So as an investor, I thought this is a really interesting area for investment.”

As the global pandemic took hold in 2020, Beckwith also volunteered to participate in several COVID vaccine studies, giving him first-hand insights into the clinical trial process.

“I was just completely shocked to see how unbelievably dysfunctional that was,” Beckwith added. “And this was one of the really big, well-funded phase-three trials. I remember having to download Internet Explorer to even sign up for the clinical trial. The website the CRO had built was on WordPress, and it didn’t have an SSL certificate. And on the clinical trial side, they were just tons of ridiculous errors. So that was a real eye-opener.”

Michael Young, one of Lindus’s two other founders, formerly served as special adviser at Downing Street, assisting the Prime Minister and U.K. Government on myriad issues across the life sciences sphere. While he was involved in a lot of work around health and biotech, Young said that much of the thinking was focused on drug approvals and NHS rollout, rather than “that bit in the middle” — that is, how the clinical trials are actually conducted.

“We just weren’t thinking about that at all,” Young told TechCrunch. “And so it was that experience that made me start digging into what is actually happening with clinical trials. We came to the conclusion that THAT is the bottleneck that’s stopping all the really cool R&D stuff that’s happening from getting to patients.”

Clinical signs

There are numerous upstarts out there seeking to make their mark in the tech-infused clinical trial space, including venture-backed companies such as Science 37, Koneksa, Curebase, and Florence Healthcare to name a few. But Lindus Health says it’s main selling point is that it’s setting out to cover the entire end-to-end process involved in running clinical trials, rather than specific “point” solutions.

“The companies we compete with are the big CROs,” Young said. “This is a massive market, and tech-first CROs have not yet got a foothold.”

For context, a contract research organization (CRO) is a third-party entity that pharmaceutical, biotech, and medical device organizations outsource some of their mission critical work to, such as clinical research. This saves them from having to do all the work themselves internally, allowing them to focus purely on their core product development. The CRO market is significant, pegged as a $77 billion market today with projections that it will grow by 70% within five years. Notable players include IQVIA, which has emerged as a $40 billion juggernaut in the CRO space, doubling its market cap in the past few years.

A typical clinical trial constitutes the initial trial design, including creating a protocol and regulatory submission package; setting up the technology platform to operate the trials; recruiting patients; delivering the program; and collating all the data. Each stage can take years, depending on the size and scope of a clinical trial, which is why Lindus is looking to streamline everything — with the exception of the ethics and regulatory process, which sits under third-party control — and improve on the existing clinical trial software on the market.

“It’s a cliche that sites (where clinical studies take place) hate the software on the market,” Young said. “We’ve invested thousands of hours speaking to site users to ensure our tool is intuitive and automates the basic tasks that they do. This results in more engaged sites and therefore faster recruitment and better data.”

Lindus Health: Recruitment
Lindus Health: Recruitment Image Credits: Lindus Health

Part of this streamlining process leans on machine learning (ML), including for the initial protocol writing phase which is typically a very “manual iterative process,” according to Young.

“The result is that, despite the best intentions, there can be contradictions or even seemingly sensible additions which hamstring a trial,” he said. “For example, adding so many exclusion criteria that a trial is almost impossible to recruit for.”

Thus, Lindus has built a “protocol generation” tool, currently at the proof-of-concept stage, trained on its own historical protocols, in addition to protocols gleaned from clinicaltrials.gov, to generate a “first draft protocol based on a small number of inputs,” according to Young. “We can then run this through a separate model that we trained on public data from ScanMedicine that highlights trial risks, and makes suggestions on how to improve the trial.”

Lindus Health AI protocol tool
Lindus Health AI protocol tool Image Credits: Lindus Health

Data capture is a major part of the clinical trial process, something that Lindus supports by allowing trial staff to capture all its data electronically from the get-go, applying AI to monitor and manage the process, while checking for data completeness and accuracy. For this, Young said the company has trained a series of models to analyze data in real-time as it’s ingested.

Lindus makes all this data available in a centralized dashboard.

“Clinical trials are in essence just a data collection exercise,” Young said. “A standard clinical trial will generate hundreds of thousands to millions of data points. The company running a clinical trial is responsible for ensuring that this data is accurate and that any data that might indicate a risk to patient safety is identified.”

Lindus Health study data dashboard
Lindus Health study data dashboard Image Credits: Lindus Health

Human condition

Lindus had hitherto raised around $6 million in funding from some of the very same investors that have joined its Series A round, including Creandum and Peter Thiel. Now, with another $18 million in the bank, the company is well-resourced to ramp up its presence across Europe and North America, where it says it has already delivered more than 80 clinical trials since its inception two years ago.

So far, Lindus has focused on a handful of conditions including depression, diabetes and insomnia. According to Beckwith, there are various factors that dictate which conditions it chooses to support, but it’s mostly about staying focused and not trying to do everything at once.

“On the practical side, our Northstar — and what differentiates us from a lot of companies in this space — is that we’ve always believed strongly that to have an impact and to make a difference, we need to run the entire clinical trial and displace CROs,” Beckwith said. “Then as a startup, we thought, ‘what are the simplest clinical trials we can run, where we can still be in charge of the whole clinical trial?’”

Thus, Lindus has purposely sought to support more common conditions. And while initially it focused on non-drug products which inherently have fewer hurdles to run clinical trials, it has since expanded into drug products and it’s now also looking to extend support to other conditions such as tinnitus, insomnia, menopause, and childhood myopia.

Beckwith added that the pharmaceutical industry has focused its R&D on more niche conditions and rare diseases in recent years, which has meant more common conditions such as type 2 diabetes have been neglected.

“Potentially, the reason that’s happened is because of the clinical trial infrastructure, because putting any patient through clinical trials has such a high cost,” Beckwith said. “So economically it’s only made sense for them to run those clinical trials where you can get an approval with few patients, and where that approval leads to a huge dollar-value for one course of treatment. So we think that our strongest competitive advantage is that we’ve just made clinical trials, on the whole, much more scalable.”

Regulation time

Lindus has secured a swathe of backers from different areas of the VC spectrum, including the aforementioned Creandum, Firstminute Capital, Seedcamp, Hambro Perks and Amino Collective. But Peter Thiel is arguably the most notable participant here, given his track record in the health tech space.

“We got connected to Peter via one of our angel investors, and when we initially spoke, he just went extremely deep on understanding the market for first principles,” Beckwith said. “For example, why the market looks the way it does with the current CROs having a terrible offering, and they have an oligopoly. And Peter’s due diligence, or ‘process’ if you like, was very different from virtually every other investor we spoke to, which is quite refreshing. Essentially, all the questions were framed around, ‘how big could Lindus Health be if we do well.’”

The fact that Thiel, alongside most of Lindus Health’s seed investors, has doubled down on his investment is indicative of how he views the clinical trial status quo. Indeed, as with just about every self-proclaimed libertarian, Thiel has never been one to welcome regulation with open arms. But he’s also a huge proponent of medical advancement, investing in countless biotech companies as part of a longer term plan to, well, live forever. As such, Thiel has been vocal about the hurdles involved in getting new medicines to market. This includes lambasting the U.S. Food and Drug Administration (FDA) over how it hinders experimental drugs from getting to market, while he also sparked a furore when he invested in a company that had previously taken its clinical trials offshore and avoided FDA oversight.

However, rules and oversight are usually in place for good reason, especially when it involves drug trials. So any company that comes along proclaiming to up-end an industry renowned for its regulatory oversight might be viewed with a little suspicion. But Young is adamant that they are focused purely on solving technical and process problems, rather than trying to push for change to regulations, something he said would be “a losing battle” as a startup. In truth, lobbying of that sort is something the big pharmaceutical companies themselves are more likely to pursue.

“Clinical trial regulations do evolve, but nothing that we’re doing is in a grey area,” he said. “We definitely think that the regulatory bodies could do more to encourage sponsors to be innovative — but within an existing regulatory framework.”

More TechCrunch

Companies are always looking for an edge, and searching for ways to encourage their employees to innovate. One way to do that is by running an internal hackathon around a…

Why companies are turning to internal hackathons

Featured Article

I’m rooting for Melinda French Gates to fix tech’s broken ‘brilliant jerk’ culture

Women in tech still face a shocking level of mistreatment at work. Melinda French Gates is one of the few working to change that.

6 hours ago
I’m rooting for Melinda French Gates to fix tech’s  broken ‘brilliant jerk’ culture

Blue Origin has successfully completed its NS-25 mission, resuming crewed flights for the first time in nearly two years. The mission brought six tourist crew members to the edge of…

Blue Origin successfully launches its first crewed mission since 2022

Creative Artists Agency (CAA), one of the top entertainment and sports talent agencies, is hoping to be at the forefront of AI protection services for celebrities in Hollywood. With many…

Hollywood agency CAA aims to help stars manage their own AI likenesses

Expedia says Rathi Murthy and Sreenivas Rachamadugu, respectively its CTO and senior vice president of core services product & engineering, are no longer employed at the travel booking company. In…

Expedia says two execs dismissed after ‘violation of company policy’

Welcome back to TechCrunch’s Week in Review. This week had two major events from OpenAI and Google. OpenAI’s spring update event saw the reveal of its new model, GPT-4o, which…

OpenAI and Google lay out their competing AI visions

When Jeffrey Wang posted to X asking if anyone wanted to go in on an order of fancy-but-affordable office nap pods, he didn’t expect the post to go viral.

With AI startups booming, nap pods and Silicon Valley hustle culture are back

OpenAI’s Superalignment team, responsible for developing ways to govern and steer “superintelligent” AI systems, was promised 20% of the company’s compute resources, according to a person from that team. But…

OpenAI created a team to control ‘superintelligent’ AI — then let it wither, source says

A new crop of early-stage startups — along with some recent VC investments — illustrates a niche emerging in the autonomous vehicle technology sector. Unlike the companies bringing robotaxis to…

VCs and the military are fueling self-driving startups that don’t need roads

When the founders of Sagetap, Sahil Khanna and Kevin Hughes, started working at early-stage enterprise software startups, they were surprised to find that the companies they worked at were trying…

Deal Dive: Sagetap looks to bring enterprise software sales into the 21st century

Keeping up with an industry as fast-moving as AI is a tall order. So until an AI can do it for you, here’s a handy roundup of recent stories in the world…

This Week in AI: OpenAI moves away from safety

After Apple loosened its App Store guidelines to permit game emulators, the retro game emulator Delta — an app 10 years in the making — hit the top of the…

Adobe comes after indie game emulator Delta for copying its logo

Meta is once again taking on its competitors by developing a feature that borrows concepts from others — in this case, BeReal and Snapchat. The company is developing a feature…

Meta’s latest experiment borrows from BeReal’s and Snapchat’s core ideas

Welcome to Startups Weekly! We’ve been drowning in AI news this week, with Google’s I/O setting the pace. And Elon Musk rages against the machine.

Startups Weekly: It’s the dawning of the age of AI — plus,  Musk is raging against the machine

IndieBio’s Bay Area incubator is about to debut its 15th cohort of biotech startups. We took special note of a few, which were making some major, bordering on ludicrous, claims…

IndieBio’s SF incubator lineup is making some wild biotech promises

YouTube TV has announced that its multiview feature for watching four streams at once is now available on Android phones and tablets. The Android launch comes two months after YouTube…

YouTube TV’s ‘multiview’ feature is now available on Android phones and tablets

Featured Article

Two Santa Cruz students uncover security bug that could let millions do their laundry for free

CSC ServiceWorks provides laundry machines to thousands of residential homes and universities, but the company ignored requests to fix a security bug.

2 days ago
Two Santa Cruz students uncover security bug that could let millions do their laundry for free

TechCrunch Disrupt 2024 is just around the corner, and the buzz is palpable. But what if we told you there’s a chance for you to not just attend, but also…

Harness the TechCrunch Effect: Host a Side Event at Disrupt 2024

Decks are all about telling a compelling story and Goodcarbon does a good job on that front. But there’s important information missing too.

Pitch Deck Teardown: Goodcarbon’s $5.5M seed deck

Slack is making it difficult for its customers if they want the company to stop using its data for model training.

Slack under attack over sneaky AI training policy

A Texas-based company that provides health insurance and benefit plans disclosed a data breach affecting almost 2.5 million people, some of whom had their Social Security number stolen. WebTPA said…

Healthcare company WebTPA discloses breach affecting 2.5 million people

Featured Article

Microsoft dodges UK antitrust scrutiny over its Mistral AI stake

Microsoft won’t be facing antitrust scrutiny in the U.K. over its recent investment into French AI startup Mistral AI.

2 days ago
Microsoft dodges UK antitrust scrutiny over its Mistral AI stake

Ember has partnered with HSBC in the U.K. so that the bank’s business customers can access Ember’s services from their online accounts.

Embedded finance is still trendy as accounting automation startup Ember partners with HSBC UK

Kudos uses AI to figure out consumer spending habits so it can then provide more personalized financial advice, like maximizing rewards and utilizing credit effectively.

Kudos lands $10M for an AI smart wallet that picks the best credit card for purchases

The EU’s warning comes after Microsoft failed to respond to a legally binding request for information that focused on its generative AI tools.

EU warns Microsoft it could be fined billions over missing GenAI risk info

The prospects for troubled banking-as-a-service startup Synapse have gone from bad to worse this week after a United States Trustee filed an emergency motion on Wednesday.  The trustee is asking…

A US Trustee wants troubled fintech Synapse to be liquidated via Chapter 7 bankruptcy, cites ‘gross mismanagement’

U.K.-based Seraphim Space is spinning up its 13th accelerator program, with nine participating companies working on a range of tech from propulsion to in-space manufacturing and space situational awareness. The…

Seraphim’s latest space accelerator welcomes nine companies

OpenAI has reached a deal with Reddit to use the social news site’s data for training AI models. In a blog post on OpenAI’s press relations site, the company said…

OpenAI inks deal to train AI on Reddit data

X users will now be able to discover posts from new Communities that are trending directly from an Explore tab within the section.

X pushes more users to Communities

For Mark Zuckerberg’s 40th birthday, his wife got him a photoshoot. Zuckerberg gives the camera a sly smile as he sits amid a carefully crafted re-creation of his childhood bedroom.…

Mark Zuckerberg’s makeover: Midlife crisis or carefully crafted rebrand?